GBP560-A

Biologic

SSK Bioscience Co., Ltd.

GBP560-A is one of 20 biologic programs targeting Japanese encephalitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

Japanese EncephalitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Japanese Encephalitis

#DrugCompanyPhaseTrials

Hepatitis a Vaccine

Sanofi

Phase 3

1 2

Prevnar

GSK

Phase 3

1 3

Havrix

GSK

Phase 3

1 4

Measles Vaccine

GSK

Phase 3

1 5

Rituxan

Roche

Phase 2

—6

Measles-Mumps-Rubella Vaccine

LLiaoning Chengda Biotechnology CO., LTD

Approved

2 7

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

1 8

Varicella Vaccine

Sanofi

Phase 3

1 9

Immunoglobulin

Sanofi

Phase 2

1 10

Rabies

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Japanese Encephalitis

NCT06680128

Clinical

Trials by Indication[1]

Japanese encephalitis1 trial

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Recruiting·SSK Bioscience Co., Ltd.·Phase 1/2·NCT06680128·402 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GBP560-A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GBP560-A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GBP560-A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SK Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: SSK Bioscience Co., Ltd.

GBP560-A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Japanese encephalitis1 trial

References

Drug Info

Quick Facts

Related News